

LEUKOCARE to publish new data on stable liquid viral vector formulations

- Data generated by LEUKOCARE feature the application of predictive accelerated aging to both increase probability of success for formulation development and enable long-term stabilization of viral vectors in liquid formulations
- LEUKOCARE's paper was selected for publication in the *Journal of Pharmaceutical Sciences*

Munich, Germany, 14 January 2020

Munich-based biotechnology company LEUKOCARE announced today that the manuscript on “Algorithm-based Liquid Formulation Development Including a DoE Concept Predicts Long-term Viral Vector Stability” was accepted for publication in the *Journal of Pharmaceutical Sciences*. LEUKOCARE's team of researchers successfully developed stable liquid formulations for adenovirus 5 (Ad5) based on a predictive approach applying its comprehensive database and rational software- and algorithm-based formulation development technology.

LEUKOCARE enabled the development of stable liquid Ad5 formulations without magnesium chloride, previously considered to be inevitable in such formulations. Moreover, the establishment of fast and high evidence-based predictive approaches for the formulation development of biologics such as viral vectors or vaccines is urgently needed to shorten timelines and reduce risk of failure for such drug product candidates.

Andreas Seidl, COO at LEUKOCARE commented “This publication demonstrates the power of innovative formulation development strategies combining in-silico approaches and state of the art wet lab operations. The obtained superior stability profiles provide new opportunities for manufacturing and application of viral vectors.”

For more information, please visit:

[https://www.jpharmsci.org/article/S0022-3549\(19\)30735-X/fulltext](https://www.jpharmsci.org/article/S0022-3549(19)30735-X/fulltext)

About LEUKOCARE AG

LEUKOCARE AG, located in Martinsried, Germany, is a biotech company specialized in the field of formulation development. LEUKOCARE develops superior formulations based on its pioneering SPS[®] formulation technology platform. The technology platform consists of two elements: a library of up to 100 different regulatory well-established and employed excipients and, moreover, a rational development approach which employs statistical software and self-learning algorithms as well as state of the art design of experiment (DoE) matrices. By utilizing these artificial intelligence elements, LEUKOCARE is able to specifically combine excipients to generate tailored formulations that meet both the drug product requirements and needs of the relevant target product profile (TPP).

LEUKOCARE's superior and innovative drug product formulations can be applied to a broad range of applications: biologics & biosimilars, vaccines & viral vectors and biofunctionalized devices.

www.leukocare.com

Contact:

Michael Scholl

michael.scholl@leukocare.com

+49 (0) 89 7801 6650